Abstract:Purpose: Thyroid-stimulating hormone receptor (TSHR) is a G-protein coupled receptor that is highly expressed on benign and malignant thyroid tissues. TSHR binding and activation has long been a component of thyroid cancer molecular imaging and radiotherapy, by promoting expression of the sodium-iodide symporter (NIS) and incorporation of I-131 into thyroid hormones. Here, we report the radiosynthesis and preclinical evaluation of a Zirconium-89 (89Zr) labeled TSHR antibody to serve as a positron emission tomography (PET) diagnostic correlate for therapeutic agents targeting TSHR without reliance on NIS. Procedures: TSHR human monoclonal antibody K1-70 was conjugated to chelator desferrioxamine-p-benzyl-isothiocyanate, followed by labeling with Zr-89, yielding the radiotracer 89Zr-DFO-TSHR-Ab. The in vitro cellar uptake and binding affinity of 89Zr-DFO-TSHR-Ab were analyzed in three new TSHR stable overexpressing tumor cell lines and their corresponding wild types (WT) with low or no TSHR expression. 89Zr-DFO-TSHR-Ab PET/CT imaging of TSHR expression was evaluated in tumor mouse models bearing one TSHR-positive tumor and other negative control with or without the coinjection of antibody K1-70, and then verified by radiotracer biodistribution study and tumor immunohistochemistry (IHC). Results: The conjugate DFO-TSHR-Ab was labeled with Zr-89 at 37 °C for 60 min and purified by PD-10 column in radiochemical yields of 68.8 ± 9.9%, radiochemical purities of 98.7 ± 0.8%, and specific activities of 19.1 ± 2.7 mCi/mg (n = 5). In vitro cell studies showed 89Zr-DFO-TSHR-Ab had significantly high uptake on TSHR expressing tumor cells with nanomolar affinity and high potency. Preclinical PET/CT imaging revealed that 89Zr-DFO-TSHR-Ab selectively detected TSHR expressing thyroid tumors and displayed improved in vivo performance with the coinjection of unlabeled TSHR antibody K1-70 leading to higher uptake in TSHR expressing tumors than parental WT tumors and physiologic tissues; this observation was confirmed by the biodistribution and immunostaining analyses. Conclusions: We synthesized 89Zr-labeled antibody K1-70 as a new radiopharmaceutical for PET imaging of TSHR. 89Zr-DFO-TSHR-Ab has high radioactive uptake and retention in TSHR expressing tumors and cleared quickly from most background tissues in mouse models. Our study demonstrated that 89Zr-DFO-TSHR-Ab has the potential for PET imaging of TSHR-positive thyroid cancer and monitoring TSHR-targeted therapy.

PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging.

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

18F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging

Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with 61Cu-Labeled Lysine-Tagged VEGF121

Generation and screening of monoclonal antibodies for immunoPET imaging of IGF1R in prostate cancer.

Pet Imaging of C-Met in Cancer with Cu-64-Labeled Hepatocyte Growth Factor

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging

A Follicle-Stimulating Hormone Receptor-Targeted Near-Infrared Fluorescent Probe for Tumor-Selective Imaging and Photothermal Therapy

Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry

Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging

Synthesis and Preliminary Study of 99Mtc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors.

In vivo small-animal PET/CT of EphB4 receptors using64Cu-labeled peptide

Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer

PET imaging of CD105/endoglin expression with a 61/64 Cu-labeled Fab antibody fragment

An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy

Synthesis and Preliminary Study of 99m Tc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors

Synthesis and Initial in Vivo Evaluation of A Radiofluorinated Sigma Receptor Radioligand for Prostate Tumor Imaging

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

Radiolabeling and Evaluation of (64)Cu-Dota-f56 Peptide Targeting Vascular Endothelial Growth Factor Receptor 1 in the Molecular Imaging of Gastric Cancer.